London Daily

Focus on the big picture.
Friday, Aug 22, 2025

‘Highly effective’ ovarian cancer treatment could help thousands of women

‘Highly effective’ ovarian cancer treatment could help thousands of women

New drug combination shrunk tumours significantly in 46% of patients with treatment-resistant form of disease
Thousands of women with ovarian cancer could benefit from a revolutionary drug combination after it was shown to shrink tumours in half of patients with an advanced form of the disease.

The pair of drugs – which work together to block the signals cancer cells need to grow – could offer a new treatment option for women with a type of ovarian cancer that rarely responds to chemotherapy or hormone therapy.

Experts said the “fantastic” results from early trials of the new drug combination, presented at the European Society for Medical Oncology congress, suggested the treatment was highly effective. They were so successful that a phase 2 trial is already under way.

Researchers said they were delighted with the outcome, and hope it could mean a significant advance in treatment if the results are replicated in larger trials.

The phase 1 trial, led by a team at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS Foundation Trust, tested the drugs VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Experts said this type of cancer tends to develop at a younger age, less than 13% of patients respond to chemotherapy and less than 14% respond to hormone therapy.

Trial results show that of the 24 patients evaluated, 46% saw their tumours shrink significantly in response to the treatment.

The outcomes were even better in patients with a particular mutation, with 64% who have KRAS-driven tumours seeing them shrink after treatment. The researchers said this indicated that tumour profiles could be used to identify which patients are most likely to benefit from the new treatment.

They said those taking part in the trial – aged between 31 and 75 – lived for an average of 23 months before their cancer progressed.

“Overcoming cancer’s ability to evolve resistance to treatment is a huge challenge for cancer research,” said Prof Kristian Helin, the chief executive of the ICR. “This study has turned a deep understanding of how cancer fuels its growth and develops resistance into a highly targeted treatment for patients who currently have few treatment options.”

Dr Susana Banerjee, also from the ICR and consultant medical oncologist and research lead at the Royal Marsden’s gynaecology unit, said: “If these findings are confirmed in larger trials, they’ll represent a significant advance in low-grade serous ovarian cancer treatment.”

The combination treatment worked even in patients who had already received an MEK inhibitor – something which can cause tumours to shrink but tends to stop working as tumours develop resistance to treatment – before the study, Banerjee said.

She added: “I am delighted that this drug combination has worked so well in a group of patients who are in urgent need of new treatments, including those who have previously been treated with a MEK inhibitor. We’re very hopeful that this could become the standard of care for women with low-grade serous ovarian cancer.”

Separately at the European Society for Medical Oncology congress, the trial of a new drug to treat a form of breast cancer was hailed as “groundbreaking”, with results said to suggest a strong trend towards improved overall survival.

AstraZeneca said Enhertu demonstrated a 72% reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer compared with a different medicine.

The trial, involving about 500 patients in Asia, Europe, North America, Oceania and South America, found there was “a strong trend towards improved overall survival” with Enhertu. But it was also pointed out that this analysis was “not yet mature and is not statistically significant”.

Dr Kotryna Temcinaite, a senior research communications manager at Breast Cancer Now, said: “These are incredibly promising results, and we now hope that further research will show whether this treatment could also offer patients precious extra time to live and be there for more moments that matter.”
Newsletter

Related Articles

0:00
0:00
Close
Ukraine Declares De Facto War on Hungary and Slovakia with Terror Drone Strikes on Their Gas Lifeline
Animated K-pop Musical ‘KPop Demon Hunters’ Becomes Netflix’s Most-Watched Original Animated Film
New York Appeals Court Voids Nearly $500 Million Civil Fraud Penalty Against Trump While Upholding Fraud Liability
Elon Musk tweeted, “Europe is dying”
Far-Right Activist Convicted of Incitement Changes Gender and Demands: "Send Me to a Women’s Prison" | The Storm in Germany
Hungary Criticizes Ukraine: "Violating Our Sovereignty"
Will this be the first country to return to negative interest rates?
Child-free hotels spark controversy
North Korea is where this 95-year-old wants to die. South Korea won’t let him go. Is this our ally or a human rights enemy?
Hong Kong Launches Regulatory Regime and Trials for HKD-Backed Stablecoins
China rehearses September 3 Victory Day parade as imagery points to ‘loyal wingman’ FH-97 family presence
Trump Called Viktor Orbán: "Why Are You Using the Veto"
Horror in the Skies: Plane Engine Exploded, Passengers Sent Farewell Messages
MSNBC Rebrands as MS NOW Amid Comcast’s Cable Spin-Off
AI in Policing: Draft One Helps Speed Up Reports but Raises Legal and Ethical Concerns
Shame in Norway: Crown Princess’s Son Accused of Four Rapes
Apple Begins Simultaneous iPhone 17 Production in India and China
A Robot to Give Birth: The Chinese Announcement That Shakes the World
Finnish MP Dies by Suicide in Parliament Building
Outrage in the Tennis World After Jannik Sinner’s Withdrawal Storm
William and Kate Are Moving House – and the New Neighbors Were Evicted
Class Action Lawsuit Against Volkswagen: Steering Wheel Switches Cause Accidents
Taylor Swift on the Way to the Super Bowl? All the Clues Stirring Up Fans
Dogfights in the Skies: Airbus on Track to Overtake Boeing and Claim Aviation Supremacy
Tim Cook Promises an AI Revolution at Apple: "One of the Most Significant Technologies of Our Generation"
Apple Expands Social Media Presence in China With RedNote Account Ahead of iPhone 17 Launch
Are AI Data Centres the Infrastructure of the Future or the Next Crisis?
Cambridge Dictionary Adds 'Skibidi,' 'Delulu,' and 'Tradwife' Amid Surge of Online Slang
Bill Barr Testifies No Evidence Implicated Trump in Epstein Case; DOJ Set to Release Records
Zelenskyy Returns to White House Flanked by European Allies as Trump Pressures Land-Swap Deal with Putin
The CEO Who Replaced 80% of Employees for the AI Revolution: "I Would Do It Again"
Emails Worth Billions: How Airlines Generate Huge Profits
Character.ai Bets on Future of AI Companionship
China Ramps Up Tax Crackdown on Overseas Investments
Japanese Office Furniture Maker Expands into Bomb Shelter Market
Intel Shares Surge on Possible U.S. Government Investment
Hurricane Erin Threatens U.S. East Coast with Dangerous Surf
EU Blocks Trade Statement Over Digital Rule Dispute
EU Sends Record Aid as Spain Battles Wildfires
JPMorgan Plans New Canary Wharf Tower
Zelenskyy and his allies say they will press Trump on security guarantees
Beijing is moving into gold and other assets, diversifying away from the dollar
Escalating Clashes in Serbia as Anti-Government Protests Spread Nationwide
The Drought in Britain and the Strange Request from the Government to Delete Old Emails
Category 5 Hurricane in the Caribbean: 'Catastrophic Storm' with Winds of 255 km/h
"No, Thanks": The Mathematical Genius Who Turned Down 1.5 Billion Dollars from Zuckerberg
The surprising hero, the ugly incident, and the criticism despite victory: "Liverpool’s defense exposed in full"
Digital Humans Move Beyond Sci-Fi: From Virtual DJs to AI Customer Agents
YouTube will start using AI to guess your age. If it’s wrong, you’ll have to prove it
Jellyfish Swarm Triggers Shutdown at Gravelines Nuclear Power Station in Northern France
×